Page last updated: 2024-11-12
bremelanotide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
bremelanotide: a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9941379 |
| CHEMBL ID | 2070241 |
| CHEBI ID | 177849 |
| SCHEMBL ID | 13574795 |
| SCHEMBL ID | 20337333 |
| MeSH ID | M0500526 |
Synonyms (40)
| Synonym |
|---|
| bremelanotide |
| (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid |
| CHEBI:177849 |
| D06569 |
| pt-141 |
| bremelanotide (usan/inn) |
| AKOS005145807 |
| unii-6y24o4f92s |
| n-acetyl-l-2-aminohexanoyl-l-alpha-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-l-lysine-(2->7)-lactam |
| l-lysine, n-acetyl-l-norleucyl-l-alpha-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, (2->7)-lactam |
| 6y24o4f92s , |
| bremelanotide [usan:inn] |
| bdbm50389769 |
| pt-141 free base |
| CHEMBL2070241 |
| bremelanotide, pt-141 |
| HS-2024 |
| SCHEMBL13574795 |
| Q-200747 |
| bremelanotide [mi] |
| l-lysine, n-acetyl-l-norleucyl-l-.alpha.-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, (2->7)-lactam |
| bremelanotide [usan] |
| n-acetyl-l-2-aminohexanoyl-l-.alpha.-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-l-lysine-(2->7)-lactam |
| bremelanotide [who-dd] |
| bremelanotide [inn] |
| SCHEMBL20337333 |
| gtpl10408 |
| pt141 |
| (1z,3s,4z,6s,7z,9r,10e,12s,13z,15s,17e,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexahydroxy-15-(((s,z)-1-hydroxy-2-(((z)-1-hydroxyethylidene)amino)hexylidene)amino)-1,4,7,10,13,18-hexaazacy |
| DB11653 |
| DTXSID40893711 , |
| Q415353 |
| 189691-06-3 (free base) |
| (3s,6s,9r,12s,15s,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-15-((s)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid |
| pt-141 (bremelanotide) |
| CS-0013839 |
| HY-18678 |
| bremelanotida |
| bremelanotidum |
| dtxcid701323799 |
Research Excerpts
Overview
Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. The MCR agonist nonselectively activates several of the receptor subtypes, of which subtype 4 (MC4R) is the most relevant at therapeutic doses.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty. " | ( Bremelanotide: First Approval. Dhillon, S; Keam, SJ, 2019) | 3.4 |
| "Bremelanotide is an MCR agonist that nonselectively activates several of the receptor subtypes, of which subtype 4 (MC4R) is the most relevant at therapeutic doses." | ( The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. Clayton, AH; Pfaus, JG; Sadiq, A; Spana, C, 2022) | 1.77 |
| "Bremelanotide is an on-demand, subcutaneous melanocortin-receptor agonist that binds to the melanocortin receptor 4 and is being developed for the treatment of female sexual dysfunction." | ( Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Jordan, R; Lucas, J; Myers, MG; White, WB, 2017) | 1.4 |
| "Bremelanotide is a synthetic peptide melanocortin analog of alpha-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R." | ( An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Diamond, LE; Earle, DC; Harning, R; Heiman, JR; Perelman, MA; Rosen, RC, 2006) | 1.27 |
| "Bremelanotide is an analogue of the naturally occurring peptide alpha-melanocyte-stimulating hormone (alpha-MSH). " | ( Bremelanotide: an overview of preclinical CNS effects on female sexual function. Gelez, H; Giuliano, F; Pfaus, J, 2007) | 3.23 |
Toxicity
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ultrastable cyclic peptide frameworks offer great potential for drug design due to their improved bioavailability compared to their linear analogues." | ( Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. Ahmad Fuaad, A; Bauer, U; Cai, M; Cheneval, O; Craik, DJ; Cromm, PM; Daly, NL; Dellsén, A; Durek, T; Harvey, PJ; Hruby, VJ; Kaas, Q; Kessler, H; Knerr, L; Larsson, N; Österlund, T; Plowright, AT; Schroeder, CI; Weidmann, J; White, AM; Zhou, Y, 2018) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Melanocortin receptor 4 | Homo sapiens (human) | Ki | 0.0167 | 0.0000 | 0.3086 | 4.8860 | AID1480165; AID1812562; AID1852336; AID677161 |
| Melanocortin receptor 5 | Homo sapiens (human) | IC50 (µMol) | 0.1980 | 0.0009 | 1.2566 | 9.5180 | AID1480166; AID1812563; AID1852340 |
| Melanocortin receptor 5 | Homo sapiens (human) | Ki | 0.0170 | 0.0005 | 3.5265 | 8.9290 | AID677160 |
| Melanocortin receptor 3 | Homo sapiens (human) | Ki | 0.1607 | 0.0001 | 0.2452 | 2.8650 | AID1480164; AID1812561; AID1852335; AID677159 |
| Melanocyte-stimulating hormone receptor | Homo sapiens (human) | Ki | 0.0030 | 0.0000 | 0.0065 | 0.0370 | AID1480163; AID1812560; AID1852334; AID677158 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Melanocortin receptor 4 | Homo sapiens (human) | EC50 (µMol) | 0.0013 | 0.0000 | 0.0911 | 2.6000 | AID1480174; AID1480175; AID1812559; AID1812567; AID1852339; AID677162 |
| Melanocortin receptor 3 | Homo sapiens (human) | EC50 (µMol) | 0.0013 | 0.0001 | 0.0127 | 0.2480 | AID1480173; AID1812558; AID1852338 |
| Melanocyte-stimulating hormone receptor | Homo sapiens (human) | EC50 (µMol) | 0.0001 | 0.0000 | 0.0080 | 0.2280 | AID1480172; AID1812557; AID1852337 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (33)
Molecular Functions (8)
Ceullar Components (3)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Melanocortin receptor 4 | Homo sapiens (human) |
| membrane | Melanocortin receptor 4 | Homo sapiens (human) |
| plasma membrane | Melanocortin receptor 4 | Homo sapiens (human) |
| cytoplasm | Melanocortin receptor 4 | Homo sapiens (human) |
| plasma membrane | Melanocortin receptor 5 | Homo sapiens (human) |
| plasma membrane | Melanocortin receptor 5 | Homo sapiens (human) |
| cytoplasm | Melanocortin receptor 5 | Homo sapiens (human) |
| plasma membrane | Melanocortin receptor 3 | Homo sapiens (human) |
| cytoplasm | Melanocortin receptor 3 | Homo sapiens (human) |
| plasma membrane | Melanocortin receptor 3 | Homo sapiens (human) |
| plasma membrane | Melanocyte-stimulating hormone receptor | Homo sapiens (human) |
| plasma membrane | Melanocyte-stimulating hormone receptor | Homo sapiens (human) |
| cytoplasm | Melanocyte-stimulating hormone receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (36)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1852334 | Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK2936E cell membrane measured after 16 to 23 hrs by 1450 microbeta trilux scintillation proximity assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1852342 | Selectivity ratio of Ki for human MC4R to Ki for human MC1R | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1480173 | Agonist activity at human MC3R expressed in low doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 45 mins by HTRF method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID1812563 | Displacement of [125I]-NDP-alpha-MSH from human MC5R expressed in HEK2936E cell membrane measured after 16-23 hrs by 1450 microbeta trilux scintillation proximity assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1852344 | Selectivity ratio of EC50 for human MC4R to EC50 for human MC1R | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1480175 | Agonist activity at human MC4R expressed in high doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 15 mins by HTRF method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID677164 | Antiobesity activity in Sprague-Dawley rat assessed as reduction of food intake at 3 mg/kg, sc qd measured after 7 to 24 hrs relative to control | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID677163 | Antiobesity activity in Sprague-Dawley rat assessed as reduction of food intake at 3 mg/kg, sc qd measured up to 7 hrs relative to control | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID677162 | Agonist activity at human recombinant MC4 receptor expressed in BHK570 cells assessed as induction of cMAP accumulation in presence of 0.1% human serum albumin | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID1812560 | Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK2936E cell membrane measured after 16-23 hrs by 1450 microbeta trilux scintillation proximity assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1812567 | Agonist activity at human melanocortin receptor 4 expressed in human T-REx-293 cells using high doxycycline assessed as stimulation of intracellular cAMP accumulation incubated for 45 mins by LANCE cAMP assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID677168 | Half life in human | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID1812558 | Agonist activity at human melanocortin receptor 3 expressed in human T-REx-293 cells assessed as stimulation of intracellular cAMP accumulation incubated for 45 mins by LANCE cAMP assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1852340 | Agonist activity at human MC5R expressed in HEK2936E cells assessed as cAMP production in presence of IBMX by time resolved fluorescence assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1852339 | Antagonist activity at human MC4R expressed in HEK2936E cells assessed as cAMP production in presence of IBMX by time resolved fluorescence assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID677158 | Displacement of [125I]-NAD-alpha-MSH from human recombinant MC1 receptor expressed in BHK570 cells after 90 mins in presence of ovalbumin | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID1480166 | Displacement of [125I]-NDP-alpha-MSH from human MC5R LBD expressed in HEK293 cell membranes incubated for 16 to 23 hrs in dark by scintillation proximity assay | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID677161 | Displacement of [125I]-NAD-alpha-MSH from MC4 receptor after 2 hrs by gamma counting in presence of ovalbumin | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID677165 | Antiobesity activity in Sprague-Dawley rat assessed as reduction of food intake at 3 mg/kg, sc qd measured after 24 to 48 hrs relative to control | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID1812562 | Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK2936E cell membrane measured after 16-23 hrs by 1450 microbeta trilux scintillation proximity assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1812561 | Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK2936E cell membrane measured after 16-23 hrs by 1450 microbeta trilux scintillation proximity assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1852338 | Agonist activity at human MC3R expressed in HEK2936E cells assessed as cAMP production in presence of IBMX by time resolved fluorescence assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1852337 | Agonist activity at human MC1R expressed in HEK2936E cells assessed as cAMP production in presence of IBMX by time resolved fluorescence assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1852343 | Selectivity ratio of EC50 for human MC3R to EC50 for human MC1R | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1480163 | Displacement of [125I]-NDP-alpha-MSH from human MC1R LBD expressed in HEK293 cell membranes incubated for 16 to 23 hrs in dark by scintillation proximity assay | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID1852341 | Selectivity ratio of Ki for human MC3R to Ki for human MC1R | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID677159 | Displacement of [125I]-NAD-alpha-MSH from human recombinant MC3 receptor expressed in BHK570 cells after 1 hr in presence of ovalbumin | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID677160 | Displacement of [125I]-NAD-alpha-MSH from human recombinant MC3 receptor human MC5 expressed in BHK570 cells after 1 hr in presence of ovalbumin | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. |
| AID1480164 | Displacement of [125I]-NDP-alpha-MSH from human MC3R LBD expressed in HEK293 cell membranes incubated for 16 to 23 hrs in dark by scintillation proximity assay | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID1812557 | Agonist activity at human melanocortin receptor 1 expressed in human T-Rex-293 cells assessed as stimulation of intracellular cAMP accumulation incubated for 45 mins by LANCE cAMP assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1480174 | Agonist activity at human MC4R expressed in low doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 45 mins by HTRF method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID1812559 | Agonist activity at human melanocortin receptor 4 expressed in human T-REx-293 cells using low doxycycline assessed as stimulation of intracellular cAMP accumulation incubated for 45 mins by LANCE cAMP assay | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework. |
| AID1480165 | Displacement of [125I]-NDP-alpha-MSH from human MC4R LBD expressed in HEK293 cell membranes incubated for 16 to 23 hrs in dark by scintillation proximity assay | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| AID1852335 | Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK2936E cell membrane measured after 16 to 23 hrs by 1450 microbeta trilux scintillation proximity assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1852336 | Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK2936E cell membrane measured after 16 to 23 hrs by 1450 microbeta trilux scintillation proximity assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. |
| AID1480172 | Agonist activity at human MC1R expressed in low doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 45 mins by HTRF method | 2018 | Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8 | Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (44)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (31.82) | 29.6817 |
| 2010's | 18 (40.91) | 24.3611 |
| 2020's | 12 (27.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 14 (29.79%) | 5.53% |
| Reviews | 15 (31.91%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (38.30%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||